Citigroup raised its rating on the stock of Lexicon Pharmaceuticals.
3 reports, 2 independent
Updated Sep 4
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup raised its rating on the stock of Lexicon Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
-
Lexicon Pharmaceuticals
biopharmaceutical company
Nothing else this week.
Related events
- Citigroup restated a buy rating on shares of Intensity Therapeutics.
- Citigroup reiterated a market outperform rating for Alphabet Inc.
- Citigroup reiterated a positive rating on BioPharma on October 7, 2026.
- Citigroup reissued a market outperform rating for Applied Digital Corporation on October 15, 2026.
- Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.